4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

April 3, 2025

Study Completion Date

April 3, 2030

Conditions
HNSCCOral CancerPD-1
Interventions
DRUG

Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses

"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"

DRUG

Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses

"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"

Trial Locations (1)

510000

RECRUITING

Sun yat-sen memorial hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER